RWA
LGND icon

Ropes Wealth Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Ropes Wealth Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-75
Closed -$6K – 681
2017
Q4 		$6K Hold
75
– – ﹤0.01% 589
2017
Q3 		$6K Buy
+75
New +$5.94K ﹤0.01% 568

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Ropes Wealth Advisors's LGND Position: Q1 2018 in Review

Ropes Wealth Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 75 shares — an estimated $6K sold.

Ropes Wealth Advisors first reported a position in LGND in Q3 2017 and held it in 2 quarters. The position peaked at $6K in Q4 2017. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

  • Ropes Wealth Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Ropes Wealth Advisors sold 75 Ligand Pharmaceuticals shares in Q1 2018, an estimated $6K.
  • Ropes Wealth Advisors first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 2 quarters.
  • Ropes Wealth Advisors's Ligand Pharmaceuticals position peaked at $6K in Q4 2017.
  • 326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Ropes Wealth Advisors's 13F filing for Q1 2018, filed 30 Apr 2018.